These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 19879055)

  • 1. Second-line treatment for malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Gianoncelli L; Lorenzi E; Santoro A
    Cancer Treat Rev; 2010 Feb; 36(1):24-32. PubMed ID: 19879055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option.
    Razak AR; Chatten KJ; Hughes AN
    Lung Cancer; 2008 May; 60(2):294-7. PubMed ID: 17919769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
    Jassem J; Ramlau R; Santoro A; Schuette W; Chemaissani A; Hong S; Blatter J; Adachi S; Hanauske A; Manegold C
    J Clin Oncol; 2008 Apr; 26(10):1698-704. PubMed ID: 18375898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
    Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
    Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A
    J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma].
    Burgin M; Gairard-Dory A-; Mennecier B; Molard A; Beretz L; Quoix A-
    Rev Pneumol Clin; 2009 Apr; 65(2):75-83. PubMed ID: 19375046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
    Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
    Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
    Budde LS; Hanna NH
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):361-8. PubMed ID: 15161435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.
    Reck M; Stahel RA; von Pawel J; Karthaus M; Korfee S; Serke M; Schuette WH; Eschbach C; Fink TH; Leschinger MI; Manegold C
    Respir Med; 2010 Jan; 104(1):142-8. PubMed ID: 19818589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; De Vincenzo F; Gianoncelli L; Simonelli M; Lorenzi E; Ripa C; Giordano L; Santoro A
    Lung Cancer; 2011 Apr; 72(1):73-7. PubMed ID: 21216487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Update of pemetrexed in thoracic oncology].
    Brechot JM; Morère JF
    Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia.
    Hasani A; Feeney K; Nowak A; Millward M
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):350-6. PubMed ID: 21114785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
    Reck M; Heigener DF; Gatzemeier U
    Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
    Hanauske AR
    Lung Cancer; 2004 Aug; 45 Suppl 1():S121-4. PubMed ID: 15261444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed therapy for malignant pleural mesothelioma.
    Puto K; Garey JS
    Ann Pharmacother; 2005 Apr; 39(4):678-83. PubMed ID: 15755794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed-cisplatin combination in mesothelioma.
    Reck M; Gatzemeier U
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):231-7. PubMed ID: 15877521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview on ongoing or planned clinical trials in Europe.
    Favaretto A
    Lung Cancer; 2005 Jul; 49 Suppl 1():S117-21. PubMed ID: 15950791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.